Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
On 2026-08-03, Corcept Therapeutics executive Sean Maduck exercised stock options for 20,305 shares of common stock at $8.27 per share and sold the same number of shares at a weighted average price of $114.7045 (range $114.49–$115.00), pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. He continues to hold 96,681 stock options and additional common stock, including unvested restricted stock awards and indirect holdings through trusts and LLCs.
Corcept Therapeutics chief accounting & technology officer Joseph Douglas Lyon reported a sale of 1,540 shares of common stock on August 3, 2026, at $114.16 per share in an open-market or private transaction. After this trade, he holds 5,495 shares, including 200, 178, 398 and 537 shares underlying unvested restricted stock awards granted on September 2, 2025, December 1, 2025, March 2, 2026 and June 1, 2026, which will fully vest on the one-year anniversaries of their grant dates if required conditions are satisfied.
CORT has filed to permit the sale of 20,000 shares of common stock on NASDAQ, expected to be effected for cash on August 4, 2026, with an indicated aggregate value of $2,256,000.00.
The transaction is tied to a stock option exercise by William Guyer. Over the prior three months, Guyer reported three separate sales of 20,000 shares each, on May 5, 2026, June 2, 2026, and July 7, 2026, with respective sale values of $1,035,501.00, $1,410,964.00, and $1,861,491.00.
Corcept Therapeutics Chief Financial Officer Mokari Atabak exercised stock options covering 80,000 shares of common stock at an exercise price of $23.06 per share on July 30, 2026, then sold 80,000 shares in multiple open-market or private transactions the same day.
The sales occurred at prices ranging from $105.305 to $120.84 per share. The option was fully exercisable and expires on February 13, 2033, with 95,833 options from this grant remaining. All reported sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025.
Corcept Therapeutics (CORT) affiliate Atabak Mokari filed a notice to sell 40,000 shares of common stock through Stifel Nicolaus & Company on or about July 30, 2026 on Nasdaq. The shares relate to stock option exercises dated February 13, 2023 under equity compensation.
The filing also lists prior sales over the past three months: 40,000 shares on June 1, 2026 for $2,800,004.00, 40,000 shares on June 15, 2026 for $3,245,900.00, and 40,000 shares on July 15, 2026 for $3,508,276.00.
Corcept Therapeutics reported strong second-quarter 2026 results, with product revenue of $256.1 million, a 32 percent increase over the same period in 2025. Korlym and its authorized generic contributed $208.6 million and newly launched Lifyorli generated $47.6 million in its first quarter of sales. Net income was $43.0 million, or $0.36 per diluted share, up from $35.1 million, or $0.29 per share, a year earlier.
Operating expenses rose to $214.8 million, driven mainly by higher selling, general and administrative spending to support Lifyorli’s launch and expansion of the Cushing’s syndrome business. Cash and investments were $544.6 million at June 30, 2026.
Management increased 2026 revenue guidance to $1.1–$1.2 billion and highlighted rapid uptake of Lifyorli in platinum-resistant ovarian cancer after its March 2026 FDA approval. The company also emphasized its late-stage pipeline, including a resubmitted NDA for relacorilant in Cushing’s syndrome with a December 17, 2026 PDUFA date, an expected EMA decision on relacorilant in ovarian cancer this year, a Phase 2b MASH study reading out by year-end, and plans for a Phase 3 ALS trial of dazucorilant.
Corcept Therapeutics director James N. Wilson reported indirect sales of 10000 shares of common stock on July 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust at weighted-average prices between $86.7777 and $89.4881 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
After these sales, that trust held 1093464.0000 shares of common stock, while separate 2025 Grantor Retained Annuity Trusts for James and Pamela Wilson each held 200000.0000 shares indirectly; Wilson has voting power over the trust shares and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics Chief Financial Officer Atabak Mokari reported option exercises and share sales in the company’s common stock. On July 15, 2026, he exercised stock options for a total of 40,000 shares at exercise prices of $23.0600 and $19.2600 per share, then sold 40,000 shares in open-market transactions at weighted average prices between $86.7760 and $89.4282 per share, with actual sale prices ranging from $86.20 to $89.43. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, and the options exercised were fully exercisable.